|
|
rcIL-15 |
|
Vaxjo ID |
244 |
|
Vaccine Adjuvant Name |
rcIL-15 |
|
Alternative Names |
recombinant canine IL-15 |
|
Adjuvant VO ID |
VO_0005728
|
|
Description |
A cytokine that promotes proliferation and activation of CD8⁺ T cells and NK cells. Used as an immunostimulatory adjuvant in dogs |
|
Stage of Development |
Research |
|
Host Species for Testing |
Dog |
|
Structure |
A recombinant protein (Asn49–Ser162 with His-tag) purified and detoxified |
|
Preparation |
Produced and purified with six His-tag residues; administered intravenously at 20 μg/kg/day for 8 days |
|
Dosage |
20 μg/kg/day IV for 8 days in beagles |
|
Function |
Type: cytokine vaccine adjuvant. Induces Th1-biased immune profile. The rcIL-15 injections also stimulated the expression of molecules and transcription factors associated with the activation and effector functions of NK cells, including CD16, NKG2D, NKp30, NKp44, NKp46, perforin, granzyme B, Ly49, T-bet, and Eomes. |
| References |
Lee et al., 2021: Lee SH, Lim YJ, Kim CJ, Yu D, Lee JJ, Won Hong J, Baek YJ, Jung JY, Shin DJ, Kim SK. Safety and immunological effects of recombinant canine IL-15 in dogs. Cytokine. 2021; 148; 155599. [PubMed: 34103211].
|
|
